Shretta Rima, Zelman Brittany, Birger Maxwell L, Haakenstad Annie, Singh Lavanya, Liu Yingying, Dieleman Joseph
Global Health Group, University of California, San Francisco, 550 16th St, 3rd Floor, Box 1224, San Francisco, CA, 94158, USA.
Swiss Tropical and Public Health Institute, Socinstrasse 57, 4002, Basel, Switzerland.
Malar J. 2017 Jul 14;16(1):251. doi: 10.1186/s12936-017-1890-0.
Donor financing for malaria has declined since 2010 and this trend is projected to continue for the foreseeable future. These reductions have a significant impact on lower burden countries actively pursuing elimination, which are usually a lesser priority for donors. While domestic spending on malaria has been growing, it varies substantially in speed and magnitude across countries. A clear understanding of spending patterns and trends in donor and domestic financing is needed to uncover critical investment gaps and opportunities.
Building on the Institute for Health Metrics and Evaluation's annual Financing Global Health research, data were collected from organizations that channel development assistance for health to the 35 countries actively pursuing malaria elimination. Where possible, development assistance for health (DAH) was categorized by spend on malaria intervention. A diverse set of data points were used to estimate government health budgets expenditure on malaria, including World Malaria Reports and government reports when available. Projections were done using regression analyses taking recipient country averages and earmarked funding into account.
Since 2010, DAH for malaria has been declining for the 35 countries actively pursuing malaria elimination (from $176 million in 2010 to $62 million in 2013). The Global Fund is the largest external financier for malaria, providing 96% of the total external funding for malaria in 2013, with vector control interventions being the highest cost driver in all regions. Government expenditure on malaria, while increasing, has not kept pace with diminishing DAH or rising national GDP rates, leading to a potential gap in service delivery needed to attain elimination.
Despite past gains, total financing available for malaria in elimination settings is declining. Health financing trends suggest that substantive policy interventions will be needed to ensure that malaria elimination is adequately financed and that available financing is effectively targeted to interventions that provide the best value for money.
自2010年以来,用于疟疾防治的捐助资金有所下降,预计在可预见的未来这一趋势仍将持续。这些资金削减对积极寻求消除疟疾的低负担国家产生了重大影响,因为这些国家通常不是捐助方的优先重点。尽管各国国内用于疟疾防治的支出一直在增长,但在增速和规模上各国差异很大。需要清楚了解捐助资金和国内资金的支出模式及趋势,以发现关键的投资缺口和机会。
基于健康指标与评估研究所的年度《全球卫生融资》研究,从向35个积极寻求消除疟疾的国家提供卫生发展援助的组织收集数据。在可能的情况下,将卫生发展援助按疟疾干预支出进行分类。使用了一系列不同的数据点来估算政府卫生预算中用于疟疾防治的支出,包括《世界疟疾报告》以及可获取的政府报告。利用回归分析进行预测,同时考虑受援国的平均水平和专项拨款。
自2010年以来,35个积极寻求消除疟疾的国家用于疟疾防治的卫生发展援助一直在下降(从2010年的1.76亿美元降至2013年的6200万美元)。全球基金是疟疾防治的最大外部资金提供者,2013年提供了疟疾防治外部资金总额的96%,病媒控制干预措施是所有地区成本最高的驱动因素。政府用于疟疾防治的支出虽然在增加,但未能跟上卫生发展援助减少或国民生产总值上升的步伐,导致在实现消除疟疾所需的服务提供方面可能存在缺口。
尽管过去取得了进展,但用于疟疾消除工作的可用资金总额仍在下降。卫生融资趋势表明,需要采取实质性的政策干预措施,以确保为疟疾消除工作提供充足资金,并确保现有资金有效地用于性价比最高的干预措施。